ArticlePLOS global public health2025
Reducing mortality in acute kidney disease through comprehensive laboratory support: Findings from the ICLATA hybrid implementation study in Zambia.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney disease (AKD) contributes significantly to morbidity and mortality, particularly in low-resource settings where limited diagnostic capacity often leads to delayed recognition and suboptimal management. We aimed to evaluate the impact of implementing a comprehensive patient-specific clinical laboratory support on clinical outcomes in AKD and to identify factors associated with mortality. We conducted a mixed-method hybrid type 3 implementation study at Livingstone University Teaching Hospital in Zambia. The study compared a retrospective non-intervention cohort (NIC; n = 39) with a prospective intervention cohort (IC; n = 39) matched for age and sex. The intervention included providing full laboratory diagnostic support for AKD management and additional patient-specific tests. The primary outcome was death within 30 days after admission regardless of whether the patient was discharged before or after the thirty-day period elapsed. Data were analyzed using logistic regression and survival analysis. The median age of the NIC (43 years, IQR 31-53) was comparable to the IC (41 years, IQR 34-53), p = 0.996. Overall, 51.3% (n = 40/78) were males. Mortality rate was significantly lower in the intervention group, with deaths occurring in 5.1% of the IC compared to 28.2% in the NIC (p = 0.012). Logistic regression confirmed the intervention as a strong independent predictor of survival (adjusted odds ratio 0.07, p = 0.009). Diagnostic accuracy improved, with fewer cases of misdiagnosis or delayed diagnosis in the IC (7.7% vs 30.8%, p = 0.019). Re-hospitalization was significantly lower in the IC (38.6% vs 61.4%, p = 0.022). ESRD was more frequently recorded in the IC due to better diagnostics, follow-up and survival. The median time-to-ESRD was substantially longer in the IC compared to NIC (140 vs 21 days, p < 0.0001). Implementation of a comprehensive patient-specific clinical laboratory support for AKD/CKD management significantly improved diagnostic precision and survival and reduced re-hospitalization. These findings highlight the value of strengthening laboratory diagnostic capacity to improve AKD outcomes in low-resource settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.